Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035991 | 0.91 | DRD2 (0.61) | POLBDRD2DRD4DRD3CHRM2 | |
| SCHEMBL1039371 | 0.90 | DRD2 (0.60) | POLBDRD2DRD4DRD3CHRM2 | |
| SCHEMBL4091274 | 0.86 | DRD2 (0.63) | POLBDRD2DRD4DRD3CHRM2 | |
| SCHEMBL1764371 | 0.85 | MEN1 (0.55) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL10844596 | 0.84 | CHRM2 (0.71) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL31256046 | 0.82 | HTR2A (0.66) | MEN1KMT2APOLBCYP1A2SMN1; SMN2 | |
| SCHEMBL29728649 | 0.80 | MEN1 (0.58) | MEN1KMT2APOLBCYP1A2CYP2C9 | |
| SCHEMBL5385733 | 0.80 | POLB (0.66) | MEN1KMT2APOLBDRD2DRD4 | |
| SCHEMBL14359370 | 0.79 | POLB (0.53) | MEN1KMT2APOLBSMN1; SMN2LMNA | |
| SCHEMBL318584 | 0.78 | HTR7 (0.59) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751116-B1 | Pyrimidine compounds and use thereof in the treatment of central nervous system disorders | ABBOTT GMBH & CO KG (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-8268815-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2361908-A1 | Pyrimidine compounds useful for the treatment of CNS diseases | Abbott GmbH & Co. KG (DE) | 2011-08-31 | — | — | EP | disclosed |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2011-05-19 | — | — | US | disclosed |
| US-7786105-B2 | Pyrimidine compounds and use thereof | ABBOTT GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-07-03 | — | — | US | disclosed |
| EP-1751116-A2 | PYRIMIDINE COMPOUNDS AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118558-A2 | PYRIMIDINE COMPOUNDS AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161322-A1 | e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease | SLC6A3, GRM3, GPR3 | MEN1 4856/4885KMT2A 4121/4885POLB 1851/4885 |
| US-20110118232-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, MC2R | MEN1 3673/4885KMT2A 3783/4885POLB 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.